AtriCure, Inc. (NASDAQ: ATRC) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $2.8B. The Maz Rating grades it against the other companies in its sector.
AtriCure, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $55.02, AtriCure, Inc. trades at 183.6x trailing earnings, 4.8x sales and 5.1x book value, with an EV/EBITDA of 69.3. Over the last twelve months it generated about $587M of revenue and $15M of net income. It runs a gross margin of 76.6%, an operating margin of 3.1% and a net margin of 2.5%. It shows return on equity of 2.9%, return on invested capital of 2.6% and a free cash flow yield of 1.9%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 4.33. Over the past 52 weeks the share price ranged from $25.36 to $66.02, with a beta of 1.21.
AtriCure, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 17 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, AtriCure, Inc. (ATRC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.26% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.93% / 30% · Interest income / Revenue 0.91% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.26% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.93% / 33% · Receivables / Mkt Cap (36m) 2.82% / 49% · Interest income / Revenue 0.91% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 2.26% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.93% / 33.33% · Receivables / Mkt Cap (24m) 2.82% / 33.33% · Interest income / Revenue 0.91% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 9.75% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24.8% / 33.33% · Receivables / Avg Assets (4Q) 10.9% / 33.33% · Interest income / Revenue 0.91% / 5% | Pass |
| FTSE | Debt / Total Assets 8.50% / 33.33% · (Cash+ST Inv) / Total Assets 26.1% / 33.33% · (Cash+Recv) / Total Assets 36.7% / 33.33% · Interest income / Revenue 0.91% / 5% | Fail |
It depends on the standard you follow. As of September 2026, AtriCure, Inc. (ATRC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. AtriCure, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.91% of each dividend: AtriCure, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.